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Objectives: Uncertainty persists as to the best lung transplant operation for
patients with pulmonary hypertension. To quantify short- and long-term
outcomes after single- and double-lung transplantation for pulmonary
hypertension, we reviewed our clinical experience. Methods: A retrospective
review of 58 lung transplants at a single institution between 1989 and 1996
was performed. Recipients had primary (n 5 19) or secondary (n 5 39)
pulmonary hypertension. Results: Thirty-seven double- and 21 single-
lung transplants were performed. The groups were well matched with
regard to preoperative characteristics. Cardiopulmonary bypass time
was longer (151 vs 250 minutes) in the double-lung group. Excluding 10
patients surviving less than 30 days (6 double- and 4 single-lung
transplants), median duration of intubation (7.5 vs 10 days), length of
stay in the intensive care unit (10 vs 16 days), and hospital stay (32 vs
52 days) were not significantly different for the single- and double-lung
groups, respectively. Actuarial survival was nearly identical, with 81%
and 84% 1-month survivals for the single- and double-lung groups, and
identical 1-year (67%) and 4-year (57%) survivals for both groups. Late
functional status was similar for recipients of single- and double-lung
grafts. During the period of this study, 58 patients with pulmonary
hypertension died on our center’s waiting list before coming to trans-
plantation. Conclusions: These data suggest that lung transplant recip-
ients with pulmonary hypertension have similar outcomes after single-
or double-lung transplantation. These results support cautious prefer-
ential application of single-lung transplantation for pulmonary hyper-
tension. (J Thorac Cardiovasc Surg 1998;115:397-403)
Lung transplantation is an established therapeuticoption for patients with end-stage pulmonary
vascular disease. We and others have been uncertain
as to the best operation to offer individuals with
severe pulmonary hypertension.1-3 To compare out-
comes after single- (SLT) and double-lung trans-
plantation (DLT) for pulmonary hypertension, we
reviewed our experience at the University of Pitts-
burgh.
Patients and methods
Patient population. Between July 1989 and April 1996,
58 primary lung transplants were performed for pulmo-
nary hypertension. Ages ranged from 14 to 61 years.
Thirty-seven patients received DLT, and 21 patients un-
derwent SLT. Pulmonary hypertension was defined as a
mean pulmonary artery pressure greater than 30 mm Hg.4
All recipients were in New York Heart Association
(NYHA) class III or IV before transplantation.
Donor selection and perioperative management. Do-
nors were deemed acceptable on the basis of previously
published criteria.5-7 Pulmonary preservation was carried
out with Euro-Collins (EC) solution through April 1991
and thereafter with University of Wisconsin (UW) solu-
tion. Alprostadil (prostaglandin E1; 500 mg) was adminis-
tered before infusion of preservation solution. Recipients
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underwent standard pulmonary function testing before
transplantation, as well as determination of left and right
ventricular ejection fractions by radionuclide examination.
Right heart catheterization data obtained in advance of
transplantation were available for all recipients. Transpul-
monary gradient was defined as mean pulmonary artery
pressure minus pulmonary capillary wedge pressure. Do-
nor characteristics were obtained from our procurement
agency. Ischemic time was defined as the interval from
donor crossclamping to reperfusion and for DLTs as the
mean ischemic time for both grafts. Operative techniques
were as previously described.8 Cardiopulmonary bypass
was used in all cases.
Early and late allograft function and survival. Postop-
erative hemodynamics and gas exchange data (ratio of
arterial oxygen tension to inspired oxygen fraction [PaO2/
FiO2]) were examined for the first 24 hours. The diagnosis
of diffuse alveolar damage was determined on the basis of
histologic findings from autopsy or biopsy specimens.
Duration of intubation, length of stay in the intensive care
unit (ICU), and patient survival were recorded. Follow-up
of 30-day survivors was 100% complete, with a mean
3.13 6 0.41 years’ follow-up in the SLT group and 3.24 6
0.42 years’ follow-up in the DLT group. The diagnosis of
obliterative bronchiolitis was based on histologic criteria.9
Statistical analysis. Statistical computations were per-
formed with JMP software (SAS Institute, Cary, N.C.).
Comparisons between preoperative patient characteris-
tics, postoperative PaO2/FiO2 ratios, pulmonary artery
pressures, late spirometry values, length of ICU and
hospital stays, and duration of intubation were done with
the use of the unpaired t test. Actuarial survivals for the
two groups were estimated by means of the Kaplan-Meier
method and were compared with the Wilcoxon rank-sum
test. Late functional status and the incidence of oblitera-
tive bronchiolitis were compared by means of the x2
likelihood ratio.
Results
Patient population: Preoperative characteristics
and transplant procedure. Table I details the preop-
erative characteristics of the SLT and DLT groups.
Systolic pulmonary artery pressures were markedly
elevated in both SLT (93.1 6 24 mm Hg) and DLT
(105.3 6 18 mm Hg) recipients (p 5 not significant).
There was remarkable similarity between the two
groups for all variables examined. Although there was
a trend toward higher mean pulmonary artery pres-
sures and lower cardiac indices in the DLT group,
these differences did not reach statistical significance.
The sole preoperative characteristic examined that
differed between the two groups was the transpulmo-
nary gradient, which was modestly higher in the DLT
group (62 vs 50 mm Hg, p 5 0.03). The frequency of
SLT and DLT was evenly distributed throughout the
years of the study (Table II). Among the 21 SLT
recipients, 10 received right lung transplants and 11
received left lung grafts.
Donor characteristics were also well matched for
both SLT and DLT groups. Pao2/FiO2 ratios were
nearly identical, as was donor age (22.5 vs 28.5 years
for SLT and DLT donors, respectively; p 5 0.17).
Nineteen recipients had primary pulmonary hy-
pertension, and 39 had secondary pulmonary hyper-
tension. Twenty-nine of the secondary pulmonary
hypertension group had Eisenmenger’s syndrome as
a result of an intracardiac defect; three patients had
scleroderma, three had pulmonary thromboembolic
disease, and one each had Osler-Weber-Rendu dis-
ease, pulmonary fibrosis, bronchopulmonary dyspla-
sia, and pulmonary artery hypoplasia.
Duration of cardiopulmonary bypass and allo-
graft ischemic times. As expected, ischemic and
cardiopulmonary bypass times were longer in the
DLT group (290 vs 333 minutes, p 5 0.04; 151 vs 250
minutes, p 5 0.0001).
Mortality. Actuarial survivals at 1 month were
81% and 84% for the SLT and DLT groups, respec-
Table I. Preoperative characteristics of patients
undergoing SLT and DLT for pulmonary
hypertension
Characteristic SLT DLT p Value
Age (yr) 36 38 NS
Sex (M/F) 14:7 28:9 NS
PO2 (mm Hg) 70 62 NS
FEV1 (%pred) 85 77 NS
RVEF 25 31 NS
LVEF 59 64 NS
PAS (mm Hg) 93 105 NS
PAD (mm Hg) 40 50 NS
PAM (mm Hg) 61 70 NS
Diagnosis (primary/secondary) 6:15 13:24 NS
CI (L/min/m2) 2.5 2.2 NS
TPG (mm Hg) 50 62 0.03
Donor PO/FiO2 467 460 NS
Po2, Room air oxygen tension; FEV1, forced expiratory volume in 1 second
(liters); RVEF, right ventricular ejection fraction; LVEF, left ventricular
ejection fraction; PAS, systolic pulmonary artery pressure; PAD, diastolic
pulmonary artery pressure; PAM, mean pulmonary artery pressure; CI,
cardiac index; TPG, transpulmonary gradient.
Table II. Operation performed by year
Year SLT DLT % SLT
1989 0 2 0
1990 1 7 12.5
1991 8 8 50
1992 4 6 40
1993 2 7 22
1994 5 1 83
1995 0 3 0
1996 1 3 25
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tively; survival was identical at 1 (67%) and 4 (57%)
years (Fig. 1). Analysis of causes of death in the first
year identified perioperative complications (bleed-
ing, technical, and cardiac) and allograft dysfunction
as the prime contributors to death during the first
month. Infection (primarily pneumonia) was re-
sponsible for the majority of deaths during the
remainder of the first posttransplant year (Table
III).
Postimplantation hemodynamics and allograft
function. Pulmonary artery pressures dropped im-
mediately after allograft implantation and remained
reduced for the first 24 hours. Mean pulmonary
artery pressures were modestly higher in the SLT
recipients 1, 12, and 24 hours after the operation
(Fig. 2). PaO2/FiO2 ratio was greater in the DLT
group 1 hour after the operation but was not
significantly different 12 and 24 hours after opera-
tion (Fig. 3).
Duration of mechanical ventilation and ICU and
hospital length of stay. Excluding 10 patients sur-
viving less than 30 days (6 DLT recipients and 4 SLT
recipients), median duration of intubation (7.5 vs 10
days), ICU length of stay (10 vs 16 days), and
hospital stay (32 vs 52 days) were not significantly
different for the SLT and DLT groups, respectively.
Diffuse alveolar damage, rejection, and oblitera-
tive bronchiolitis. The incidence of histologically
proven diffuse alveolar damage was similar for both
groups: 43% for SLT and 51% for DLT recipients.
Episodes of treated rejection in the first 100 days
(mean 2.8 episodes for SLT recipients and 2.9
episodes for DLT recipients) were also similar for
both groups. Although the incidence of obliterative
bronchiolitis was higher among SLT recipients (9/
21, 42.9%), it was not significantly different from the
incidence among DLT recipients (9/37, 24.3%, p 5
0.14). Mean serum creatinine 1 year after transplan-
Fig. 1. Actuarial survival of SLT and DLT recipients.
Table III. Cause of death in the first year after
transplantation
POD SLT POD DLT
Day 0-30
5 Unrecognized PFO/
graft failure
0 Intraoperative circula-
tory collapse
15 Airway dehiscence 1 Intraoperative cardiac
failure
19 Donor brain emboli,
pneumonia
2 Allograft dysfunction
21 Graft failure 3 Operative bleeding
15 Venous cerebral
thrombosis
24 Sepsis
Day 31-365
39 Pneumonia 31 Graft failure (severe
DAD)
101 PTLD 96 Pneumonia
225 Pneumonia 99 Pneumonia
104 Persistent rejection
161 Pneumonia
217 Pneumonia
POD, Postoperative day; PFO, patent foramen ovale; DAD, diffuse alveo-
lar damage; PTLD, posttransplantation lymphoproliferative disease.
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tation was 1.6 mg/dl for both SLT and DLT recipi-
ents.
Follow-up spirometry and functional status. Per-
cent predicted forced expiratory volume in 1 second
was similar for SLT and DLT recipients at up to 4
years after transplantation and was well preserved
(Table IV). Review of functional status of current
survivors demonstrated that more than 90% were in
NYHA functional class I or II at the time of this
report (Table V).
Status of patients with pulmonary hypertension
on waiting list. During the period of this study, 58
patients with pulmonary hypertension died on our
center’s waiting list before coming to transplanta-
tion.
Discussion
This report describes an 8-year single-center ex-
perience with lung transplantation for recipients
with pulmonary hypertension and contrasts the early
and late-term results of patients receiving SLT and
DLT. That the SLT and DLT groups were remark-
ably homogeneous in terms of preoperative charac-
teristics reflects in part our uncertainty as to the
better operation for these patients. Although this
comparison is retrospective, comparison of out-
comes between these groups is valid given their
marked preoperative similarity (Table I). Although
assignment to SLT or DLT was not randomized, this
decision was often influenced by variables indepen-
dent of the recipient, primarily donor organ avail-
ability.
Characteristics common to both SLT and DLT
groups included a preponderance of women (42:16),
markedly depressed right ventricular function be-
fore transplantation, and preserved left ventricular
function. Although preoperative pulmonary artery
pressures were somewhat higher in the group un-
dergoing DLT, there was substantial overlap and
this difference did not achieve statistical (or clinical)
significance. Application of SLT and DLT to pa-
tients with primary and secondary pulmonary hyper-
tension was evenly distributed among the two
groups. There was a trend toward a lower cardiac
index in the DLT group (2.5 vs 2.2), although the
difference was not statistically significant. Transpul-
monary gradient was lower for the SLT than for the
DLT group (50 vs 62 mm Hg, p 5 0.03).
Implantation of one rather than two lungs carries
the advantage of a shorter exposure to cardiopul-
monary bypass and a shortened ischemic time.
Mean ischemic time was 43 minutes less and dura-
tion of cardiopulmonary bypass 99 minutes less for
SLT in this series.
An important measure of the quality of early graft
function is the duration of mechanical ventilatory
support, as well as length of stay in the ICU. The
presence of two pulmonary allografts did not confer
additional benefit based on these measures of out-
come. We in fact found that median duration of
intubation and ICU length of stay were somewhat
shorter in the SLT group.
Although others10 have reported a higher inci-
dence of obliterative bronchiolitis in SLT recipients
with pulmonary hypertension, we did not observe a
significant difference between the two groups, al-
though there was a trend toward more prevalent
obliterative bronchiolitis in the SLT group. At
present the sample sizes in the two groups are too
Fig. 2. Preoperative and postoperative mean pulmonary
artery pressures (PAmean) for SLT and DLT recipients.
Results are expressed as mean 6 standard error of the
mean.
Fig. 3. Donor and postoperative PaO2/FiO2 ratios for
SLTs and DLTs. Results are expressed as mean 6 stan-
dard error of the mean.
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small to detect a difference. It is possible that
obliterative bronchiolitis is detected earlier in the
SLT group as a result of a smaller volume of
functioning pulmonary parenchyma and that, with
further follow-up, this difference will become clear.
A proposed disadvantage of SLT for pulmonary
hypertension has been the possibility of poorer
long-term functional results with a smaller volume
of functioning lung parenchyma. A recent report
from the St. Louis group11 comparing long-term
functional outcome after SLT and DLT for emphy-
sema found that DLT provides superior long-term
functional outcome as assessed by spirometry and
exercise tolerance, as well as a trend toward im-
proved late survival, and attributed these findings to
the presence of more functioning lung allograft
parenchyma after the onset of obliterative bronchi-
olitis. In contrast, we found identical functional
status in both SLT and DLT groups late after
transplantation for pulmonary hypertension. Spi-
rometry demonstrated relatively well-preserved pul-
monary function that was similar for both SLT and
DLT groups 4 years after transplantation.
As has been previously reported, hemodynamics
after SLT for pulmonary hypertension are charac-
terized by a rapid and sustained drop in pulmonary
artery pressures, substantial improvement in right
ventricular function, and a preponderance (.90%)
of pulmonary blood flow to the allograft as a result
of high pulmonary vascular resistance in the remain-
ing native lung.2, 12 In contrast, blood flow is evenly
distributed between the two grafts in DLT recipi-
ents. The larger vascular bed in the DLT group
yielded only modestly lower pulmonary artery pres-
sures after transplantation and had no effect on
early oxygenation. Boujoukos and colleagues13 have
compared early allograft function in SLT recipients
with emphysema and pulmonary hypertension. They
convincingly demonstrate that excessive allograft
blood flow and pulmonary hypertension are not
major contributors to early graft dysfunction. Our
experience with SLT and DLT for pulmonary hy-
pertension does not support an early functional
advantage to transplanting two lungs based on sim-
ilar lengths of ventilator support and duration of
support in the ICU.
Our data supporting the application of SLT to
patients with pulmonary hypertension are remarkably
similar to those of Pasque and colleagues,14 who
reported the results of 34 SLTs for pulmonary hyper-
tension. Their series documents a rapid normalization
of pulmonary artery pressures after transplantation
(mean pulmonary artery pressure 25 6 5 mm Hg,
postoperative day 1) that is maintained over the long
term after transplantation (mean pulmonary artery
pressure 21 6 6 mm Hg 4 years after operation).
Survival in their experience was similar to ours, with a
3-year survival of 61%. Pasque and coworkers14 also
report excellent long-term functional status, with 91%
of current survivors in NYHA class I or II, as we found
in our cohort.
In contrast to the present report, others have re-
ported poorer outcomes after SLT for pulmonary
hypertension. Review of the International Society for
Heart and Lung Transplantation (ISHLT) registry
data suggests a marginally worse outcome for SLT as
opposed to DLTs for patients with primary pulmonary
hypertension. Thirty-month survival for DLT recipi-
ents (n 5 199) was 60%, as opposed to 48.4% (n 5
195) for SLT recipients.15 This is in contrast to our
experience with patients having primary pulmonary
hypertension: a 3-year survival of 70% for SLT (n 5 6)
and 56% (n 5 13) for DLT. Similarly, Pasque and
colleagues reported 68% survival for 24 patients with
primary pulmonary hypertension receiving SLT. It is
notable that the ISHLT registry data identifies equiv-
alent numbers of SLTs and DLTs for primary pulmo-
nary hypertension.
The reality of limited pulmonary donor availabil-
ity is demonstrated by the deaths of 58 patients with
Table IV. FEV1 for SLT and DLT recipients (% predicted, 6SEM)
Group 6 mo 1 yr 2 yr 3 yr 4 yr
SLT 87.7 6 6.5 84.8 6 6.4 85.5 6 6.2 80.9 6 7.5 69.2 6 9.0
DLT 71.0 6 5.0 71.8 6 5.3 74.3 6 4.9 78.7 6 5.3 70.8 6 7.0
p Value 0.05 0.13 0.17 0.81 0.89
N 38 35 29 24 16
FEV1, Forced expiratory volume in 1 second; SEM, standard error of the mean
Table V. Late functional status among currently
surviving lung transplant recipients
NYHA class
I II III IV
SLT 5 4 1 0
DLT 10 10 2 0
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pulmonary hypertension cleared for transplantation
and waiting on the list at our institution during the
time period of this study. The data reported here
document similar early and late outcomes for recip-
ients with pulmonary hypertension receiving SLT or
DLT. Before this review our program had become
progressively more conservative relative to SLT for
patients with pulmonary hypertension because the
majority of other programs have been more accept-
ing of a DLT-only philosophy and admittedly these
patients require more physician management early
after transplantation. Currently we readily accept
single lungs for those with modest and even supra-
systemic pulmonary pressures. So long as left ven-
tricular function is reasonable, we believe that SLT
will immediately reduce pulmonary pressures to a
degree that preoperative right heart dysfunction will
not preclude success. Although we encourage cau-
tious application of SLT for recipients with pulmo-
nary hypertension, we believe that certain circum-
stances mandate DLT. We will avoid SLT if the
donor is undersized relative to the recipient or if the
donor lung is less than pristine. Given the opportu-
nity to nearly double the supply of donor lungs, we
believe that the operation of choice for recipients
with primary or secondary pulmonary hypertension
is SLT.
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Discussion
Dr. Bruce Reitz (Stanford, Calif.). My bias has been that
for pulmonary hypertension, a DLT was a better option
than an SLT, although the bias is built on a relatively small
experience at Stanford in the late 1980s and early 1990s,
many of these patients being operated on by Dr. Vaughn
Starnes. It seemed to us that the mortality was similar, but
in the period from 1 to 3 years, the effects of obliterative
bronchiolitis were more prominent in the DLT group;
perhaps they had less reserve once obliterative bronchi-
olitis became apparent. That does not seem to be the case
with your data, so I guess we need to rethink our bias.
I have several questions: Six patients underwent lung
transplantation for pulmonary hypertension in the more
recent years of your series, 1995 and 1996. Five of the six
had DLT and the other patient had SLT. Are the conclu-
sions of your paper now changing your philosophy? Are
you now offering only SLTs to these patients?
Dr. Gammie. The distribution of SLTs and DLTs
throughout the years of our study was more or less even.
The last 2 years reflects donor lung availability. Given the
results of this study, however, we are shifting our emphasis
toward SLT, and that is our operation of choice. There are
a few instances in which we would not perform an SLT,
specifically if we have an undersized donor lung or a
marginal donor lung. We require a pristine lung of
adequate size.
Dr. Reitz. Does the age of the recipient play any role in
determining whether you would do a DLT or an SLT? For
example, we believe that a DLT with more pulmonary
tissue has a better functional capacity, and so we have
tended to recommend DLT for younger recipients. Would
that come into your thinking in pulmonary hypertension,
or would you still advocate SLT even for a young patient?
Dr. Gammie. That has been the bias of some of the
surgeons at our institution, but our data really do not
support that conclusion. The average age of patients in the
SLT group was 36 years and in the DLT group 38 years, so
there was no difference in age between the two popula-
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tions. On the basis of the measurements that we have
done, there is no difference in long-term survival or
functional status. Although that had been an underlying
bias, I think that an SLT is preferable for any age group.
We have to remember that we are able to serve two
patients instead of just one patient by doing an SLT
operation.
Dr. Reitz. I agree with you. However, the trend from the
Registry seems to indicate that more and more DLTs are
being performed while the number of SLTs remains the
same or decreases. Your data indicating the efficacy of
SLT are encouraging, but in practice many people do not
seem to accept that.
My final question concerns the management of these
patients. It had seemed to us that management of patients
was more difficult after SLT. In your data, the results were
the reverse: the SLT group spent less time on the venti-
lator and had shorter ICU stays. What made management
of the DLT group more difficult? Was it simply the longer
operation, the longer ischemic time, or was there no
specific cause?
Dr. Gammie. Patients undergoing SLT will be kept
sedated for the first 24 to 48 hours after the operation.
Your are right. They do tend to be quite labile. The
information that I presented was time on the ventilator,
and we really did not find much of a difference. The
disadvantages of DLT are precisely those that you men-
tioned: the longer time in the operating room and the
longer time on cardiopulmonary bypass. They had almost
twice as long a time on bypass, and I think that definitely
influences their postoperative course. SLT is a quick
operation, and it removes the primary modes of death of
these patients—the most common cause of death being
progressive right ventricular failure and the second most
common cause, sudden cardiac death. When we perform
an SLT, we remove this specter of death, and we really see
no late deaths from these causes. Instead, they are re-
placed with the standard causes of death after lung
transplantation—infection and rejection.
Dr. David M. Follette (Sacramento, Calif.). I have one
question. Investigators at the University of Pennsylvania
and other institutions seem to have found that the degree
of pulmonary hypertension relative to the systemic blood
pressure is important. Patients with supersystemic pulmo-
nary artery pressures tend to have a much greater risk with
SLT, and these investigators have moved to DLT in that
group with much improved results. Have you compared
the systemic to the pulmonary artery pressure, and have
you seen any difference in your survival with those partic-
ular patients?
Dr. Gammie. I am aware of their bias. We did not
specifically look at that issue, although we looked at the
pulmonary artery pressure, which was not different in the
two groups and approached systemic pressure. We also
looked at systemic blood pressure and found no significant
difference in the two groups. I believe that we would not
see a difference.
Dr. Douglas E. Wood (Seattle, Wash.). Despite your
data showing no significant difference in the preoperative
characteristics, if one looks at that list, there is a differ-
ence, albeit not significant statistically, in virtually every
category. When you take that as a total, I wonder whether
patient selection actually created more of a bias in your
study than you would like to think. I actually agree with
your result; it is our own bias as well to do SLTs as much
as possible for pulmonary hypertension, both primary and
secondary, but I would be cautious about your conclu-
sions. Do you think that this would be a good project to
study in a prospective fashion in a multiinstitutional basis,
perhaps under the aegis of the Lung Transplant Study
Group?
Dr. Gammie. That is an excellent suggestion. This was
not a prospective randomized trial, and there were some
trends, albeit insignificant, in selection of these patients. I
stand by the data and I think that your suggestion of
looking at this in a prospective fashion would not be
unreasonable.
Dr. Paul F. Waters (Los Angeles, Calif.). I have a couple
of questions. I am concerned that the conclusion is a little
too strong. As someone who does both these operations,
I do not think they are the same operation. The manage-
ment of these patients differs, being more difficult with
SLT recipients. How are these patients managed in the
postoperative period? Did all or some of them get nitric
oxide? Did they all need it? Did they all get alprostadil
(prostaglandin E1)? Was there any difference in the way
they were managed and, subsequently, the outcome?
Second, if I understand you correctly, you use whatever
is available. If a single lung is available, you perform SLT.
If two lungs are available, you do DLT. Is that correct or
is there any other processing involved?
Dr. Gammie. I agree with you. The SLT recipients do
tend to have a rockier course in the first 24 to 48 hours
after transplantation. We have not used nitric oxide
routinely nor do we give alprostadil to all patients, but
rather on an as-needed basis. Until recently, the decision
to perform an SLT or a DLT was influenced both by the
selection committee, which applied biases, as well as
organ donor availability. We currently preferentially do
SLTs for patients with pulmonary hypertension, provided
that we have a good quality lung of adequate size.
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